Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
Completed · Phase 3 · Has a placebo group
Conditions studied: Smoking Cessation
In brief
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
Key facts
- Study ID
- NCT00285012
- Run by
- Pfizer
- People needed
- 504
- Starts
- 2006-05-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2010-04-20
Who can join
Age: 35 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit.
- mild to moderate COPD confirmed by spirometry
- Subjects must have a clinical diagnosis of COPD.
You may not qualify if…
- Subjects who have made a serious attempt to quit smoking in the past 3 months.
- Subjects who have been previously randomized in a study that has included varenicline.
Where it is running
- Pfizer Investigational Site — Birmingham, Alabama, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Denver, Colorado, United States
- Pfizer Investigational Site — Farmington, Connecticut, United States
- Pfizer Investigational Site — Farmington, Connecticut, United States
- Pfizer Investigational Site — Miami, Florida, United States
- Pfizer Investigational Site — Lexington, Kentucky, United States
- Pfizer Investigational Site — Portland, Maine, United States
- Pfizer Investigational Site — North Dartmouth, Massachusetts, United States
- Pfizer Investigational Site — Rochester, Minnesota, United States
- Pfizer Investigational Site — Omaha, Nebraska, United States
- Pfizer Investigational Site — Rochester, New York, United States
- Pfizer Investigational Site — Chapel Hill, North Carolina, United States
- Pfizer Investigational Site — Chapel Hill, North Carolina, United States
- Pfizer Investigational Site — Raleigh, North Carolina, United States
- Pfizer Investigational Site — Winston-Salem, North Carolina, United States
- Pfizer Investigational Site — Winston-Salem, North Carolina, United States
- Pfizer Investigational Site — Portland, Oregon, United States
- Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
- Pfizer Investigational Site — Nashville, Tennessee, United States
- Pfizer Investigational Site — Houston, Texas, United States
- Pfizer Investigational Site — Brest, France
- Pfizer Investigational Site — Montpellier, France
- Pfizer Investigational Site — Nice, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.